410 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Frazier Financial Advisors LLC

Frazier Financial Advisors LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 410 shares of the company’s stock, valued at approximately $239,000.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. Lipe & Dalton acquired a new position in Eli Lilly and Company during the fourth quarter worth $26,000. Tidemark LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth $29,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the third quarter worth $36,000. St. Johns Investment Management Company LLC raised its position in Eli Lilly and Company by 123.3% during the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after acquiring an additional 37 shares during the period. Finally, Family CFO Inc acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at about $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 0.0 %

Shares of NYSE LLY traded down $0.35 during midday trading on Wednesday, hitting $802.82. The company’s stock had a trading volume of 1,766,155 shares, compared to its average volume of 3,005,803. The business’s fifty day simple moving average is $762.62 and its two-hundred day simple moving average is $689.24. The firm has a market capitalization of $763.01 billion, a price-to-earnings ratio of 117.74, a price-to-earnings-growth ratio of 1.55 and a beta of 0.37. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $816.61. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.62 earnings per share. On average, equities analysts predict that Eli Lilly and Company will post 13.78 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 annualized dividend and a yield of 0.65%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on LLY shares. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Argus raised their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Truist Financial raised their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Finally, JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $769.53.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.